basiliximab

IV (Adults and Children ≥35 kg): 20 mg given 2 hr before transplantation; repeated 4 days after transplantation. Second dose should be withheld if complication or graft loss occurs.
IV (Children <35 kg): 10 mg given 2 hr before transplantation; repeated 4 days after transplantation. Second dose should be withheld if complication or graft loss occurs.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to and blocks specific interleukin-2 receptor sites on activated T lymphocytes.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: Immunosuppressant agents

Pharmacologic Classification: monoclonal antibodies

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Moderately distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 7.2 days.

Time/Action Profile ⬆ ⬇

(effect on immune function)

ROUTE	ONSET	PEAK	DURATION
IV	2 hr	unknown	36 days

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Explain that patient will need to resume lifelong therapy with other immunosuppressive drugs after completion of basiliximab course.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Advise patient of signs and symptoms of hypersensitivity reactions and HF. Advise to seek immediate medical attention if symptoms occur.
May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response is known.
Instruct patient to continue to avoid crowds and persons with known infections, because basiliximab also suppresses the immune system.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Patients of reproductive potential should use effective contraceptive measures before beginning treatment, during, and for 4 mo after completion of treatment. Encourage patients who become pregnant or whose partners have received basiliximab to register with the Transplant Pregnancy Registry International by calling 1-877-955-6877 or going to https://www.transplantpregnancyregistry.org.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0078- Novartis Pharmaceuticals Corporation
- 0078-0331- Simulect
  - 0078-0331-84- 1 VIAL, SINGLE-USE in 1 CARTON (0078-0331-84) / 5 mL in 1 VIAL, SINGLE-USE

0078- Novartis Pharmaceuticals Corporation
- 0078-0393- Simulect
  - 0078-0393-61- 1 VIAL, SINGLE-USE in 1 CARTON (0078-0393-61) / 2.5 mL in 1 VIAL, SINGLE-USE

66447- NOVARTIS PHARMA SAS
- 66447-0102-
  - 66447-0102-9- 2 kg in 1 BOTTLE (66447-0102-9)

68225- Patheon Italia S.p.A.
- 68225-237-
  - 68225-237-00- 2232 VIAL, GLASS in 1 BOX (68225-237-00) / 2.5 mL in 1 VIAL, GLASS

68225- Patheon Italia S.p.A.
- 68225-238-
  - 68225-238-00- 2232 VIAL, GLASS in 1 BOX (68225-238-00) / 2.5 mL in 1 VIAL, GLASS